Collectively, our multi-cancer analysis newly identified LBH overexpression in colon, rectal, pancreatic, esophageal, bladder, kidney, prostate, testicular, head & neck cancer, sarcoma, and in aggressive leukemia and lymphoma subtypes, revealing DNA hypomethylation as a possible mechanism of aberrant LBH activation. Here, LBH is linked to leukemia.